John Doane, MD
Ophthalmology · Leawood, KSNPI 1851384119
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $351,223 of the $496,276 with a category attached, or 70.8%. Carl Zeiss Meditec, Inc. accounts for 63.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $119,876 and has fallen 61.8% since, to $45,820 in 2025. Among ophthalmology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $2286.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$316K
- Rxsight Inc$136K
- Carl Zeiss Meditec USA, Inc.$36K
- Alcon$8K
- Carl Zeiss Meditec AG$445
- Novartis$380
- plus $235 from 7 others
Across 96 payments — averaging $5800.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec, Inc.$333K
- Rxsight Inc$224K
What the payments were for
- Consulting fees$351,22371%
- Speaking & faculty fees$126,42625%
- Travel & lodging$5,8731%
- Food & beverage$7,3521%
- Education$4,9081%
- Gifts$4300%
- Entertainment$490%
- Other$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 121 | $315,788 |
| Rxsight Inc | 46 | $135,515 |
| Carl Zeiss Meditec USA, Inc. | 25 | $36,043 |
| Alcon | 10 | $7,870 |
| Carl Zeiss Meditec AG | 3 | $445 |
| Novartis | 5 | $380 |
| Bausch & Lomb Americas Inc. | 1 | $91 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $44 |
| Staar Surgical Company | 1 | $43 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Dompe US, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $15 |
| The Cameron-ehlen Group, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$305,332
- RXSIGHT CONTACT LENS$115,214
- RXSIGHT INJECTOR CARTRIDGE$115,214
- RXSIGHT INJECTOR HANDPIECE$115,214
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$115,214
- LIGHT ADJUSTABLE LENS (LAL)$95,900
- MEL 90$73,148
- CIRRUS HD-OCT$34,875
- IOLMaster 700$26,943
- CIRRUS 6000 with AngioPlex$22,125
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$19,314
- MEL 80$18,750
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$17,693
- QUATERA 700$15,797
- CLARUS$15,563
- VERACITY SURGICAL$14,364
- ATLAS 500$12,693
- CALLISTO eye$11,177
- Humphrey HFA$11,063
- FORUM$9,563
How this compares
$496,276 in reported general payments places this provider in the 95th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 1,154 | $47,509 |
| Ciprofloxacin Hcl | 822 | $8,687 |
| XiidraLifitegrast | 12 | $8,183 |
| Latanoprost | 71 | $586 |
| Ketorolac Tromethamine | 15 | $583 |
| Acyclovir | 32 | $330 |
| Timolol Maleate | 29 | $239 |
| Ofloxacin | 14 | $170 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 19 | $147 |
| Amoxicillin | 15 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $91 | $8,18312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Leawood
- Matthew SniegowskiLeawood$22K
- Timothy WallineLeawood$5K
- Alaina GerenLeawood$4K
- Kevin PikeyLeawood$3K
- Alexander VuLeawood$2K
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.